ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Stomach Cancer
Colorectal Cancer
Esophageal Cancer
Prostatic Cancer

Adenocarcinoma trials near Berlin, BE, DEU:

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

plus trastuzumab alone for a maximum systemic treatment duration of one year in patients with Her-2 positive localized esophagogastric adenocarcinoma...

Active, not recruiting
Esophagogastric Adenocarcinoma
Drug: Pembrolizumab
Drug: Trastuzumab

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 12 other locations

Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (NeoART)

trastuzumab-deruxtecan containing combinational treatment regimens in patients with HER2 positive, locally advanced, resectable esophagogastric adenocarcinoma...

Enrolling
Esophagogastric Adenocarcinoma
Drug: Trastuzumab deruxtecan + 5FU/LV
Drug: Trastuzumab deruxtecan + FLO

Phase 1, Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 10 other locations

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Active, not recruiting
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Berlin, Germany and 155 other locations

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Enrolling
Gastroesophageal Cancer
Drug: Rescue medication
Drug: Supportive care measures

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Berlin, Germany and 152 other locations

Bemarituzumab in FGFR2b+ Patients with Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed At Least One Prior Line of Palliative Chemotherapy

response in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. The main questi...

Enrolling
Metastatic Gastro-esophageal Adenocarcinoma
Drug: bemarituzumab, trifluridine/tipiracil
Drug: bemarituzumab, irinotecan

Phase 2

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Berlin, Germany and 29 other locations

Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma (ANTELOPE)

arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in ...

Enrolling
Non-Small Cell Lung Cancer Metastatic
Drug: Cisplatin
Drug: Atezolizumab

Phase 4

Nikolaj Frost MD

Berlin, Germany and 30 other locations

A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (DisTinGuish)

as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Tislelizumab 200mg
Drug: DKN-01 400mg

Phase 2

Leap Therapeutics

Berlin, Berlin, Germany and 47 other locations

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)

II clinical trial.Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination chemoth...

Enrolling
Metastasis
Oligometastatic Disease
Drug: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)

Phase 2

University of Cologne

Berlin, Germany and 10 other locations

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: AZD0901
Drug: Docetaxel

Phase 3

AstraZeneca
AstraZeneca

Berlin, Germany and 182 other locations

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Drug: 5-FU
Biological: Lenvatinib

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Berlin, Germany and 176 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems